Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1386357

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1386357

Pneumococcal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

Pneumococcal Vaccine Trends and Forecast

The future of the global pneumococcal vaccine market looks promising with opportunities in the pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine markets. The global pneumococcal vaccine market is expected to reach an estimated $11.24 billion by 2030 with a CAGR of 4.8% from 2024 to 2030. The major drivers for this market are growing awareness of the importance of pneumococcal vaccination, development of new and innovative pneumococcal vaccines, and government initiatives to promote pneumococcal vaccination.

A more than 150-page report is developed to help in your business decisions.

Pneumococcal Vaccine by Segment

The study includes a forecast for the global pneumococcal vaccine by product type, vaccine type, and region.

Pneumococcal Vaccine Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • Prevnar 13
  • Synflorix
  • Pneumovax23

Pneumococcal Vaccine Market by Vaccine Type [Shipment Analysis by Value from 2018 to 2030]:

  • Pneumococcal Conjugate Vaccine
  • Pneumococcal Polysaccharide Vaccine

Pneumococcal Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Pneumococcal Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pneumococcal vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pneumococcal vaccine companies profiled in this report include-

  • GlaxoSmithKline
  • Pfizer
  • Merck
  • CSL
  • Serum Institute of India

Pneumococcal Vaccine Market Insights

Lucintel forecasts that prevnar 13 is expected to witness highest growth over the forecast period due to its ability to protect children and adults from pneumococcal diseases caused by 13 serotypes of streptococcus pneumoniae.

Within this market, pneumococcal conjugate vaccine is expected to witness higher growth over the forecast period due to its capacity to prevent pneumococcal disease in children and young adults.

Features of the Global Pneumococcal Vaccine Market

Market Size Estimates: Pneumococcal vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Pneumococcal vaccine market size by product type, vaccine type, and region in terms of value ($B).

Regional Analysis: Pneumococcal vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, vaccine types, and regions for the pneumococcal vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pneumococcal vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the pneumococcal vaccine market size?

Answer: The global pneumococcal vaccine market is expected to reach an estimated $11.24 billion by 2030.

Q.2 What is the growth forecast for pneumococcal vaccine market?

Answer: The global pneumococcal vaccine market is expected to grow with a CAGR of 4.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the pneumococcal vaccine market?

Answer: The major drivers for this market are growing awareness of the importance of pneumococcal vaccination, development of new and innovative pneumococcal vaccines, and government initiatives to promote pneumococcal vaccination.

Q4. What are the major segments for pneumococcal vaccine market?

Answer: The future of the pneumococcal vaccine market looks promising with opportunities in the pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine markets.

Q5. Who are the key pneumococcal vaccine market companies?

Answer: Some of the key pneumococcal vaccine companies are as follows:

  • GlaxoSmithKline
  • Pfizer
  • Merck
  • CSL
  • Serum Institute of India

Q6. Which pneumococcal vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that prevnar 13 is expected to witness highest growth over the forecast period due to its ability to protect children and adults from pneumococcal diseases caused by 13 serotypes of streptococcus pneumoniae.

Q7. In pneumococcal vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to high prevalence of pneumococcal disease among population and presence of well-established healthcare system in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the pneumococcal vaccine market by product type (prevnar 13, synflorix, and pneumovax23), vaccine type (pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Pneumococcal Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Pneumococcal Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Pneumococcal Vaccine Market by Product Type
    • 3.3.1: Prevnar 13
    • 3.3.2: Synflorix
    • 3.3.3: Pneumovax23
  • 3.4: Global Pneumococcal Vaccine Market by Vaccine Type
    • 3.4.1: Pneumococcal Conjugate Vaccine
    • 3.4.2: Pneumococcal Polysaccharide Vaccine

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Pneumococcal Vaccine Market by Region
  • 4.2: North American Pneumococcal Vaccine Market
    • 4.2.2: North American Pneumococcal Vaccine Market by Vaccine Type: Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine
  • 4.3: European Pneumococcal Vaccine Market
    • 4.3.1: European Pneumococcal Vaccine Market by Product Type: Prevnar 13, Synflorix, and Pneumovax23
    • 4.3.2: European Pneumococcal Vaccine Market by Vaccine Type: Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine
  • 4.4: APAC Pneumococcal Vaccine Market
    • 4.4.1: APAC Pneumococcal Vaccine Market by Product Type: Prevnar 13, Synflorix, and Pneumovax23
    • 4.4.2: APAC Pneumococcal Vaccine Market by Vaccine Type: Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine
  • 4.5: ROW Pneumococcal Vaccine Market
    • 4.5.1: ROW Pneumococcal Vaccine Market by Product Type: Prevnar 13, Synflorix, and Pneumovax23
    • 4.5.2: ROW Pneumococcal Vaccine Market by Vaccine Type: Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Pneumococcal Vaccine Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Pneumococcal Vaccine Market by Vaccine Type
    • 6.1.3: Growth Opportunities for the Global Pneumococcal Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Pneumococcal Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Pneumococcal Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Pneumococcal Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: GlaxoSmithKline
  • 7.2: Pfizer
  • 7.3: Merck
  • 7.4: CSL
  • 7.5: Serum Institute of India
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!